COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase 3/4 Clinical Study to Evaluate the Efficacy and Safety of Aramchol Versus Placebo in Subjects With NASH (ARMOR) (ARMOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04104321
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : November 4, 2019
Information provided by (Responsible Party):
Galmed Pharmaceuticals Ltd ( Galmed Research and Development, Ltd. )

Brief Summary:

A double-blind placebo controlled randomized Phase 3/4 study in subjects with nonalcoholic steatohepatitis (NASH) and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes.

The primary objectives of the study are to evaluate the effect of Aramchol as compared to placebo on NASH resolution, fibrosis improvement and clinical outcomes related to progression of liver disease.

Subjects will be randomized to receive Aramchol 300mg BID or matching placebo in a 2:1 randomization ratio.

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis (NASH) Drug: Aramchol Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With Nonalcoholic Steatohepatitis (NASH) The ARMOR Study
Actual Study Start Date : September 23, 2019
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : December 2024

Arm Intervention/treatment
Experimental: Aramchol
Aramchol 300 mg oral tablet
Drug: Aramchol
Aramchol 300 mg BID

Placebo Comparator: Placebo
Placebo matching oral tablet
Drug: Placebo
Placebo BID

Primary Outcome Measures :
  1. To evaluate the effect of Aramchol compared to placebo on liver histology by assessing the following primary endpoints: [ Time Frame: 52 weeks ]
    • Resolution of NASH defined as the Proportion (%) of subjects with resolution of NASH (defined by Ballooning of 0 and inflammation 0-1) and no worsening of liver fibrosis, or
    • Improvement in Fibrosis defined as the Proportion (%) of subjects with improvement in liver fibrosis greater than or equal to one stage and no worsening of steatohepatitis.

  2. To evaluate the effect of Aramchol compared to placebo on composite long-term outcome [ Time Frame: at End of Study, latest at 5 years from last subject's randomization ]
    Proportion (%) of subjects experiencing at least 1 of the following events: All-cause mortality, Liver transplant, Histological progression to cirrhosis, MELD score >15, Hospitalization due to hepatic decompensation event(s).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Male or female age 18 to 75 years
  2. Histological confirmation of NASH on a diagnostic liver biopsy by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period)
  3. Total NAS Score 4 or more with at least 1 in each component of the NAS Score (steatosis ≥1 AND inflammation ≥1 AND ballooning ≥1)
  4. Fibrosis Stage must be 2 or 3
  5. Body mass index (BMI) between 25kg/m2 and 40 kg/m2
  6. AST>20 IU/L
  7. Type 2 diabetes mellitus or prediabetes
  8. For subjects with type 2 diabetes, glycemia must be controlled
  9. Females of childbearing potential must practice a highly effective method of contraception throughout the study period and for 1 month after treatment discontinuation.
  10. Able to understand the nature of the study and to provide signature of the written informed consent.

Key Exclusion Criteria:

  1. Histologically documented liver cirrhosis (fibrosis stage 4)
  2. Inability or unwillingness to undergo a liver biopsy
  3. Abnormal synthetic liver function
  4. ALT or AST >5× upper limit of normal (ULN)
  5. Platelet count < 150,000mm3
  6. Alkaline phosphatase ≥2× ULN
  7. Known or suspected hepatocellular carcinoma (HCC)
  8. Model for End-Stage Liver Disease (MELD) score > 12
  9. Prior history or presence of decompensated liver disease
  10. Other (acute or chronic) coexisting liver disease based on medical history and/or centralized review of liver histology)
  11. Known alcohol and/or any other drug abuse or dependence in the last five years
  12. Weight loss of more than 5% within 3 months prior to screening
  13. History of bariatric surgery within 5 years of liver biopsy or planned surgery for weight reduction
  14. Treatment with drugs that may cause NAFLD within 12 months prior to liver biopsy
  15. Treatment with some anti-diabetic medications; Unless started prior to biopsy (timeframe depending on drug) and stable
  16. Current or planned treatment with immunosuppressive drugs
  17. Evidence of any other unstable or untreated clinically significant disease
  18. Uncontrolled hypertension
  19. Any other condition that in the opinion of the Investigator warrants exclusion from the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04104321

Layout table for location contacts
Contact: Galmed +972-3-6938448

Layout table for location information
United States, Texas
Texas Clinical Research Institute, LLC Recruiting
Arlington, Texas, United States, 76012
Sponsors and Collaborators
Galmed Research and Development, Ltd.
Layout table for additonal information
Responsible Party: Galmed Research and Development, Ltd. Identifier: NCT04104321    
Other Study ID Numbers: Aramchol-018
First Posted: September 26, 2019    Key Record Dates
Last Update Posted: November 4, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Galmed Pharmaceuticals Ltd ( Galmed Research and Development, Ltd. ):
liver fibrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases